Loading
Unfavourable cancer of unknown primary is the large majority of cases, where a metastatic adenocarcinoma or poorly differentiated carcinoma fits no recognised pattern and its origin cannot be found. Treatment has long been general-purpose platinum chemotherapy, but CUPISCO showed that matching drugs to the tumour's genetic faults after short chemotherapy holds the disease longer.
Most patients with cancer of unknown primary do not fit a favourable subset. They have adenocarcinoma or poorly differentiated carcinoma in the liver, lungs, bones or several sites at once, are often unwell at diagnosis, and survival is short; performance status and serum lactate dehydrogenase are the strongest predictors of survival. For thirty years treatment has been empirical: carboplatin with paclitaxel or gemcitabine with cisplatin, regimens chosen because they work across many cancers, with response rates around a third and median survival of about nine to twelve months in trial populations and shorter in the clinic. Randomised trials of classifier-directed site-specific chemotherapy (GEFCAPI 04, Lancet Oncology 2019, and a Japanese trial) did not improve on this, and PD-1 antibodies produced responses in about a fifth of patients in the NivoCUP trial (Annals of Oncology 2022) and the CUPISCO immunotherapy arm, leading to nivolumab's approval for CUP in Japan in 2021.
The CUPISCO trial (Lancet 2024) changed the framing. After three cycles of platinum-based induction chemotherapy, 636 patients with unfavourable CUP whose disease had not progressed were randomised to continue chemotherapy or to switch to molecularly guided therapy chosen by a tumour board from comprehensive genomic profiling, including targeted drugs for actionable alterations and atezolizumab for tumours with high mutational burden or without a target: progression-free survival rose from 4.4 to 6.1 months, a modest but real gain that established genomic profiling as part of the standard work-up. About a third of patients carry an actionable alteration (HER2, BRAF V600E, NTRK fusions, MSI or high tumour mutational burden, and others), and the ESMO 2023 guideline recommends profiling for all patients fit for treatment; circulating tumour DNA is an alternative when tissue is scarce. Trials now test targeted agents, immunotherapy combinations and antibody-drug conjugates with chemotherapy in first line, and DNA-methylation classifiers are being revisited as a route to site-specific immunotherapy choices. Early palliative care and honest discussion of prognosis are part of standard management.
Averages across everyone diagnosed, often years ago. A median is the middle of a group: half the people counted lived longer than the figure shown, and some lived far longer. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Exclude favourable subsets; comprehensive genomic profiling of tissue or plasma; assess performance status and lactate dehydrogenase.
Platinum-based doublet (carboplatin-paclitaxel or gemcitabine-cisplatin) for three cycles, then continuation or a switch to molecularly guided therapy where an actionable alteration is found (CUPISCO).
Tumour-agnostic therapies: pembrolizumab or nivolumab for MSI-high or high tumour mutational burden, NTRK inhibitors, BRAF and MEK inhibitors, HER2-directed therapy.
Alternative chemotherapy, PD-1 antibody if not given (nivolumab approved in Japan), or trial entry; trials of antibody-drug conjugates and immunotherapy combinations.
Best supportive care with early palliative care involvement.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Comprehensive genomic profiling at diagnosis is now justified for unfavourable cancer of unknown primary, with a switch to a matched drug after induction chemotherapy when an actionable target is found.
The split between favourable and unfavourable cancer of unknown primary on OnCo, and the treatment on each page, follow this guideline.
Predicting the primary site by gene expression and treating accordingly is not better than empirical chemotherapy, so guidelines do not recommend it; the field moved to genomic profiling for actionable targets instead.
Query for this cancer: (TITLE:"Cancer of unknown primary, unfavourable" OR ABSTRACT:"Cancer of unknown primary, unfavourable" OR TITLE:"adenocarcinoma and poorly differentiated carcinoma" OR ABSTRACT:"adenocarcinoma and poorly differentiated carcinoma" OR TITLE:"Unfavourable-risk CUP" OR ABSTRACT:"Unfavourable-risk CUP" OR TITLE:"Poor-prognosis CUP" OR ABSTRACT:"Poor-prognosis CUP" OR TITLE:"CUP adenocarcinoma with liver or multiple metastases" OR ABSTRACT:"CUP adenocarcinoma with liver or multiple metastases" OR TITLE:"Non-specific CUP" OR ABSTRACT:"Non-specific CUP") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma), not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Bleeding that does not stop by itself, bleeding from more than one site, or new bruising in several places or one large area.
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
Dose by Calvert formula using GFR (see the calculators).
Immunotherapy can attack hormone-producing glands: most often the thyroid (usually ending in an under-active thyroid needing lifelong tablets), and less often the pituitary (hypophysitis) or adrenal glands, which can be life-threatening if missed.
During chemotherapy a temperature over 37.5 C or below 36 C, shivering, or feeling unwell even with a normal temperature means ringing the hospital's 24-hour line straight away; breathing very fast, confusion, mottled skin or no urine in a day means 999.
See all on the product pages:CarboplatinGemcitabine + cisplatinNivolumabPaclitaxel / nab-paclitaxelPembrolizumab·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Cancer of unknown primary, unfavourable, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.